FOGHORN THERAPEUTICS INC. - COMMON STOCK

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

05 May 2025 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

01 May 2025 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

28 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

15 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

25 Mar 2025 16:35:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

06 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

25 Feb 2025 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

16 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

12 Nov 2024 07:54:32 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

04 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

10 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in the BMO Oncology Summit

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

22 May 2024 18:21:05 By Nasdaq GlobeNewswire

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

20 May 2024 07:58:16 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

06 May 2024 07:00:00 By Nasdaq GlobeNewswire